These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 27462918)

  • 1. Variations within 3'-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy.
    Yang Y; Gao W; Ding X; Xu W; Liu D; Su B; Sun Y
    Oncotarget; 2017 Mar; 8(10):16313-16324. PubMed ID: 27462918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy.
    Yang Y; Xu W; Liu D; Ding X; Su B; Sun Y; Gao W
    Tumour Biol; 2016 Jun; 37(6):7785-96. PubMed ID: 26695147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of MSH3 polymorphisms with response and survival in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
    Xu XL; Yao YL; Xu WZ; Feng JG; Mao WM
    Genet Mol Res; 2015 Apr; 14(2):3525-33. PubMed ID: 25966119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A genetic variation in microRNA target site of ETS2 is associated with clinical outcomes of paclitaxel-cisplatin chemotherapy in non-small cell lung cancer.
    Hong MJ; Lee SY; Choi JE; Jin CC; Kang HJ; Baek SA; Lee SY; Shin KM; Jeong JY; Lee WK; Yoo SS; Lee J; Cha SI; Kim CH; Son JW; Park JY
    Oncotarget; 2016 Mar; 7(13):15948-58. PubMed ID: 26893365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A genetic variant within MDM4 3'UTR miRNA binding site is associated with HPV16-positive tumors and survival of oropharyngeal cancer.
    Zhang Y; Sturgis EM; Wei P; Liu H; Wang Z; Ma Y; Liu C; Gu KJ; Wei Q; Li G
    Mol Carcinog; 2019 Dec; 58(12):2276-2285. PubMed ID: 31513313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-binding site SNPs in deregulated genes are associated with clinical outcome of non-small cell lung cancer.
    Xu J; Tian S; Yin Z; Wu S; Liu L; Qian Y; Pei D; Gao W; Xu J; Yin Y; Liu P; Shu Y
    Lung Cancer; 2014 Sep; 85(3):442-8. PubMed ID: 24997136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Regulatory MDM4 Genetic Variant Locating in the Binding Sequence of Multiple MicroRNAs Contributes to Susceptibility of Small Cell Lung Cancer.
    Gao F; Xiong X; Pan W; Yang X; Zhou C; Yuan Q; Zhou L; Yang M
    PLoS One; 2015; 10(8):e0135647. PubMed ID: 26274820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC.
    Qian J; Liu H; Gu S; Wu Q; Zhao X; Wu W; Wang H; Wang J; Chen H; Zhang W; Wei Q; Jin L; Lu D
    Clin Lung Cancer; 2015 Sep; 16(5):e37-53. PubMed ID: 25818095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
    Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
    Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A genetic polymorphism in pre-miR-27a confers clinical outcome of non-small cell lung cancer in a Chinese population.
    Xu J; Yin Z; Shen H; Gao W; Qian Y; Pei D; Liu L; Shu Y
    PLoS One; 2013; 8(11):e79135. PubMed ID: 24223174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of polymorphisms in translesion synthesis genes with prognosis of advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Zhang X; Chen Q; Chen J; He C; Mao J; Dai Y; Yang X; Hu W; Zhu C; Chen B
    J Surg Oncol; 2016 Jan; 113(1):17-23. PubMed ID: 26611653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
    Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
    Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A genetic variation in microRNA target site of KRT81 gene is associated with survival in early-stage non-small-cell lung cancer.
    Lee SY; Choi JE; Jeon HS; Hong MJ; Choi YY; Kang HG; Yoo SS; Lee EB; Jeong JY; Lee WK; Lee J; Cha SI; Kim CH; Kim YT; Jheon S; Son JW; Park JY
    Ann Oncol; 2015 Jun; 26(6):1142-1148. PubMed ID: 25716425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms of BCL2 and BAX Genes Associate with Outcomes in Advanced Non-small cell lung cancer Patients treated with platinum-based Chemotherapy.
    Peng Y; Wang L; Qing Y; Li C; Ren T; Li Q; Li M; Zhang S; Shan J; Wang G; Yang Z; Wang D
    Sci Rep; 2015 Dec; 5():17766. PubMed ID: 26656462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An illegitimate microRNA target site within the 3' UTR of MDM4 affects ovarian cancer progression and chemosensitivity.
    Wynendaele J; Böhnke A; Leucci E; Nielsen SJ; Lambertz I; Hammer S; Sbrzesny N; Kubitza D; Wolf A; Gradhand E; Balschun K; Braicu I; Sehouli J; Darb-Esfahani S; Denkert C; Thomssen C; Hauptmann S; Lund A; Marine JC; Bartel F
    Cancer Res; 2010 Dec; 70(23):9641-9. PubMed ID: 21084273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of functional LIG4 polymorphism on platinum-based chemotherapy response and survival in non-small cell lung cancer.
    Jiang YH; Xu XL; Ruan HH; Xu WZ; Li D; Feng JG; Han QB; Mao WM
    Med Oncol; 2014 May; 31(5):959. PubMed ID: 24722796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic variants of NBS1 predict clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer in Chinese.
    Xu JL; Hu LM; Huang MD; Zhao W; Yin YM; Hu ZB; Ma HX; Shen HB; Shu YQ
    Asian Pac J Cancer Prev; 2012; 13(3):851-6. PubMed ID: 22631660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment.
    Qian J; Gu S; Wu Q; Zhao X; Wu W; Gao Z; Zhang W; Tan X; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
    Chest; 2012 Sep; 142(3):680-689. PubMed ID: 22441531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.